M. Patricia Rivera, MD, ATSF, elected in 2020, serves as the President.
Dr. Rivera is the C. Jane Davis & C. Robert Davis Distinguished Professor in Pulmonary Medicine, as well as chief, Division of Pulmonary and Critical Care Medicine at the University of Rochester Medical Center. She also serves as adjunct professor of Medicine at the University of North Carolina at Chapel Hill, and the co-director of the North Carolina Lung Screening Registry. Dr. Rivera originally founded the Multidisciplinary Lung Cancer Screening Program at UNC. Dr. Rivera joined the ATS in 1988 and is a member of the Thoracic Oncology Assembly. 1
Irina Petrache, MD, ATSF, elected in 2021, serves as the President-Elect. Dr. Petrache will serve as President in 2024-2025.
Dr. Petrache is Professor of Medicine at National Jewish Health and at the University of Colorado. She also serves as chief of Pulmonary, Critical Care and Sleep Medicine, associate vice president of Faculty Development, and Wollowick Chair in COPD Research at National Jewish Health. Dr. Petrache joined the ATS in 1997 and is a member of the Respiratory Cell & Molecular Biology Assembly. 2
Raed A. Dweik, MD, MBA, ATSF, elected in 2023, serves as the Secretary. Dr. Dweik will serve as President in 2025-2026.
Dr. Dweik currently holds the E. Tom and Erica Meyer Endowed Professorship and serves as chair of Pulmonary and Critical Care Medicine and enterprise chief of the Integrated Hospital Care Institute - IHI (Pulmonary, Critical Care, Infectious Disease, Emergency Services, Urgent and Express Care, Anesthesiology, Hospital Medicine, Perioperative Medicine) at Cleveland Clinic Health System (CCHS). He joined the ATS in 1994 and is a member of the Pulmonary Circulation Assembly.3
Gregory Downey, MD, ATSF, elected in 2019, serves as the Immediate Past-President.
Dr. Downey is a professor of Medicine, Pediatrics, and Immunology and Genomic Medicine at National Jewish Health where he also serves as executive vice president of Academic Affairs, and provost. He is also professor of Medicine and Immunology and Microbiology and associate dean of Health Affairs at the University of Colorado in Denver. Dr. Downey conducts research supported by the National Institutes of Health focused on lung injury, repair, and fibrosis and the effects of particulate matter on respiratory health. He joined the ATS in 1987 and is a member of the Allergy Immunology & Inflammation Assembly. 4
Jesse Roman, MD, ATSF, elected in 2022, serves as the ATS Treasurer through 2025.
Dr. Roman is the Ludwig Kind Professor of Medicine and enterprise division chief, Pulmonary, Allergy and Critical Care Medicine. He also serves as CEO of the Jane & Leonard Korman Respiratory Institute of Jefferson Health and National Jewish Health. Dr. Roman conducts NIH-sponsored research in lung tissue remodeling and is involved in clinical trials. He joined the ATS in 1988 and is a member of the Respiratory Cell & Molecular Biology Assembly. 5
Karen J. Collishaw, MPP, CAE, appointed as Chief Executive Officer in May 2018.
Prior to joining the ATS, Ms. Collishaw was the President & CEO of the Community Health Accreditation Program (CHAP), an independent, not-for-profit accrediting body for community-based health care organizations. Previously, Ms. Collishaw served in executive leadership positions with two professional medical societies--the American Academy of Dermatology and the American College of Cardiology (ACC). She was responsible for activities related to science, research, advocacy and quality, and managed ACC’s annual scientific session.
Following the completion of a Bachelor of Arts in Government from Cornell University, Ms. Collishaw started her career working for the U.S. House of Representatives and then in Battelle Memorial Institute’s Washington office. She earned a Master of Public Policy degree from Georgetown University, is a Certified Association Executive, and past president of the American Association of Medical Society Executives.
- 2023 Disclosure of Potential Conflicts of Interest Relevant to ATS Activities: Dr. Rivera conducts research supported by the National Institutes of Health focused on implementation and dissemination of lung cancer screening in real-world settings and comorbidity and functional status of persons undergoing lung cancer screening. She serves as a consultant for American Board of Internal Medicine for pulmonary boards writing committee. She serves as a consultant for the American Cancer Society. back to text
- 2023 Disclosure of Potential Conflicts of Interests Relevant to ATS Activities: Dr. Petrache is a scientific co-founder of Allinaire Therapeutics which develops novel therapeutics for pulmonary arterial hypertension (PAH) and other pulmonary diseases, including EMAP II. She conducted research supported by Allinaire, which evolved from work of Dr. Petrache and colleagues as part of the University of Indiana Center for Biomedical Innovation and is funded by Biomotiv. She served as a consultant for Ceramedix for antibody therapies. She participated in National Institutes of Health-supported research on sphingolipids and the effect of vaping on lung parenchyma. back to text
- 2023 Disclosure of Potential Conflicts of Interests Relevant to ATS Activities: Dr. Dweik is an investigator and inventor on a Joint Development and Option agreement between Cleveland Clinic and BreathTech Corporation, a wholly owned subsidiary of Astrotech Corporation. The aim of the research project is to develop a rapid breath test for coronavirus infection or related indicators. Dr. Dweik is entitled to commercialization revenues as an inventor on the intellectual property. back to text
- 2023 Disclosure of Potential Conflicts of Interests Relevant to ATS Activities: Dr. Downey has served on the Board of Directors of the Lovelace Respiratory Institute and as a consultant for Angion in the development of novel anti-fibrotic compounds. No payments have been received from Angion. He previously served as a consultant for Biomotiv in the development of novel anti-inflammatory compounds. He served as a consultant for Altimmune for antiviral therapies. Dr. Downey served as a consultant for Translate Bio for ARDS treatment. He has served on a scientific advisory committee for the LAM Foundation. back to text
- 2023 Disclosure of Potential Conflicts of Interests Relevant to ATS Activities: Dr. Roman received industry-sponsored research support to his institution for anti-fibrotic treatment from F. Hoffmann-LaRoche, Horizon Therapeutics, Galapagos, Syneos Health, Boehringer Ingelheim, Bellerophon Therapeutics.. He served as a consultant for Boehringer Ingelheim developing national registry designed to obtain real life data about interstitial lung disorders. He serves on the DSMB for an NIH sponsored trial. back to text